Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers

Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers

The NavDx<sup>®</sup> blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integrated into clinical practice...

Full description

Bibliographic Details
Main Authors: Alicia Gunning, Sunil Kumar, Cassin Kimmel Williams, Barry M. Berger, Stephen P. Naber, Piyush B. Gupta, Catherine Del Vecchio Fitz, Charlotte Kuperwasser
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Diagnostics
Subjects:
NavDx
HPV
oropharyngeal
cancer
papillomavirus
profiling assay
Online Access:https://www.mdpi.com/2075-4418/13/4/725

Internet

https://www.mdpi.com/2075-4418/13/4/725

Similar Items